Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
U.S. regulatory submission for patients ages 12-17 planned for third quarter 2018
A pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat moderate-to-se...
Continue Reading →
